Aldesleukin is currently used to treat people with kidney ora skin cancer, but researchers think it could be ‘revolutionise heart attack treatment’, as it increases levels of a rare white blood cell that protects the organ
A cancer drug could help speed up recovery sopra heart attack patients and cut the risk of a second attack, experts say.
An injection of aldesleukin increases levels of a rare white blood cell that protects the heart, researchers at Cambridge University have found.
Experts are now trialling the drug – normally used to treat skin and kidney cancer – 60 heart attack patients sopra England after it showed promising results sopra small studies.
If the ongoing trials are as successful, the researchers said the treatment could ‘revolutionise heart attack treatment’.
More than 100,000 people sopra the UK are hospitalised every year paio to heart attacks, while the number is 805,000 sopra the US.
Around one sopra five people go to have a second heart attack.
More than 100,000 people sopra the UK are hospitalised every year paio to heart attacks, while around 805,000 people sopra the US suffer a heart attack. And around one sopra five people will go to have a second heart attack
Heart attack survivors often get a concoction of blood thinning drugs, such as Aspirin, and ACE inhibitors, which widen the blood vessels to increase the amount of blood that the heart can pump around the .
They may also receive beta blockers, which slow the heart to protect against a second heart attack, and cholesterol-lowering statins.
But about one sopra five people who have had a heart attack will be readmitted to the hospital for a second one within five years.
HEART ATTACKS EXPLAINED
Figures suggest there are 100,000 hospital visits because of heart attacks sopra the UK each year, while there are around 800,000 annually sopra the US.
A heart attack, known medically as a myocardial infarction, occurs when the supply of blood to the heart is suddenly blocked.
Symptoms include chest pain, shortness of breath, and feeling weak and anxious.
Heart attacks are commonly caused by coronary heart disease, which can be brought by smoking, high blood pressure and diabetes.
Treatment is usually medication to dissolve blots clots ora surgery to remove the blockage.
Sopravvissuto your risk by not smoking, exercising regularly and drinking sopra moderation.
Heart attacks are different to a cardiac arrest, which occurs when the heart suddenly stops pumping blood around the , usually paio to a problem with electrical signals sopra the organ.
Aldesleukin is currently used to treat people with kidney ora skin cancer.
It works by increasing the number and activity of white blood cells, which can help the franco system kill cancer cells.
The Cambridge scientists first tested the drug mice, before launching a clinical trial of 12 heart attack patients sopra their 60s, while an additional four patients received a placebo injection.
The researchers found both the mice and human trials of aldesleukin increased levels of franco cells that protect the heart, which are called innate type 2 lymphocyte (ILC2).
Dr Tian Zhao, a British Heart Foundation clinical lecturer sopra cardiovascular medicine at the University of Cambridge, said: ‘Right now, there is voto negativo way to stop the franco system, which gets activated after a heart attack, from mistakenly damaging the heart.
‘If our clinical trial shows that aldesleukin works the same way sopra people as it does sopra mice, by harnessing the ‘good cops’ of our franco system, we may have found a way to help the heart heal after a heart attack.’
The researchers studied mice that were unable to produce ILC2 and found that their hearts did not recover as well after a heart attack.
But mice that could produce ILC2 had reduced heart scarring and better heart function after a heart attack.
And a low parte of aldesleukin given to patients led to higher levels of ILC2.
The ILC2 cells have previously been found to sopravvissuto the inflammation sopra arteries.
By targeting the inflammation caused by the ’s franco response to a heart attack, the experts hope the drug will also sopravvissuto a person’s risk of having a second heart attack.
Researchers are not yet sure how much the treatment will cost, as the currently licensed dosage is 12 times higher than the one given sopra the trials.
Professor Metin Avkiran, associate medical director at the British Heart Foundation, said: ‘Every five minutes someone is admitted to a UK hospital paio to a heart attack.
‘Thanks to research, heart attacks are now treatable, and seven out of ten people will survive. However, many heart attack survivors will still be left with damaged hearts.
‘This research reveals a new approach that has the potential to both help heal hearts damaged by a heart attack and sopravvissuto the risk of a further heart attack.
‘If clinical trials results confirm these early research findings, drugs that activate ILC2 could revolutionise heart attack treatment.’